Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Mateja Legan) .

1 - 2 / 2
First pagePrevious page1Next pageLast page
1.
New marker of angiogenesis CD105 (endoglin): diagnostic, prognostic and therapeutic role
Mateja Legan, 2005, review article

Abstract: Background. The well established notion that malignant tumours depend on angiogenesis to grow and metastasize focused the investigators interest on tumour vasculature into visualization and validation. Panendothelial markers (CD31, CD34, F8) and CD105 are differentially expressed in angiogenic and normal vessel endothelial cells. Since the former are excellent markers for the normal vasculature, CD105 (endoglin) is more suitable for identifying tumour angiogenesis. Endoglin is a transforming growth factor (TGF)- beta binding receptor, preferentially expressed on endothelial cells of angiogenic tissues, essential for angiogenesis and vascular development. Conclusions. Tumor microvessel density expressed by CD105 immunohistochemical staining in paraffin-embedded tissue section correlates significantly with tumour aggressiveness and prognosis in many solid tumours. Also, targeting of tumour neovasculature specific antigens offers the possibility of future therapeutic approaches.
Published in DiRROS: 14.02.2024; Views: 137; Downloads: 32
.pdf Full text (96,88 KB)

2.
The role of cyclooxygenase-2 in the malignant tissue and possible applicability of cyclooxygenase-2 inhibitors in the therapy of cancer
Mateja Legan, 2003, review article

Abstract: Cyclooxygenase-2 (COX 2), an inducible prostaglandin (PG) synthase, is elevated in many types of malignant and pre-malignant tissues. This enzyme is localized in neoplastic (epithelial) cells, microvascular endothelial cells, and stromal fibroblasts. Through the released PG it enhances carcinogenesis with increasing angiogenesis, inhibiting apoptosis, activating matrix metalloproteinases, suppressing of cell mediated antitumor immune response andprotection against damage by cytotoxic agents. Evidences from in vitro studies, studies on animal models as well as first clinical outcomes suggest that the inhibition of COX 2 may suppress carcinogenesis by affecting a numberof pathways: inhibiting angiogenesis, invasiveness of tumors and promoting apoptosis. References forecast that COX 2 inhibitors, mostly COX 2 selective inhibitors, may get a role in the therapy of cancer as an adjuvant therapy or as an co-chemotherapeutic agent. The purpose of the present articleis to summarize the most important facts about the role of COX 2 in themalignant tissue and discuss possible ways for potential therapeutic place of COX 2 inhibitors in clinical practice.
Published in DiRROS: 06.02.2024; Views: 148; Downloads: 33
.pdf Full text (205,37 KB)
Search done in 0.08 sec.
Back to top